Glucocorticoid-induced Osteopenia in Children
Completed
Conditions studied: Crohn's Disease, Nephrotic Syndrome
In brief
The purpose of this study is to characterize the skeletal deficits and risk factors for impaired skeletal development in children requiring glucocorticoid therapy. We will compare the bone health of children treated with prednisone for nephrotic syndrome (NS with those treated with prednisone for Crohn's Disease (CD). Childhood NS usually responds to prednisone and is not characterized by pathologies that can impact on bone. In contrast, CD is treated with prednisone, but is independently associated with poor growth and maturation, nutritional deficiencies and inflammation. Due to the differences in the diseases, this comparison will allow us to distinguish between the prednisone-related and disease-related effects on bone in the two disease states.
Key facts
- Study ID
- NCT00289328
- Run by
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- People needed
- 550
- Starts
- 2001-11-01
- Expected to finish
- 2006-04-01
- Last updated by the study team
- 2010-03-02
Who can join
Age: 5 and older, up to 21. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- ages 5-21
- clinical and pathological diagnosis of Crohn's Disease within the last 2 years
- clinical diagnosis of nephrotic syndrome and taking corticosteroids within the last year
- normal renal function GFR>75 ml/min/1.73m2
- healthy controls
You may not qualify if…
- other major medical conditions affecting growth and/or bone health
- significant cognitive or developmental disorders (if child is unable to cooperate sufficiently)
- nonambulatory
Where it is running
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.